Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure

Cell Cycle

Volumn 12, Issue 4, 2013, Pages 684-697

  Huang, Yiping ^a   Kesselman, Dafna ^a   Kizub, Darya ^a   Guerrero Preston, Rafael ^a   Ratovitski, Edward A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; DNA protein interactions; MicroRNAs; P53; P63; Squamous cell carcinomas

Indexed keywords

CISPLATIN; DELTANP63ALPHA PROTEIN; MESSENGER RNA; MICRORNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 84874630110     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23598     Document Type: Article

References (82)

1. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002; 118:923-32; PMID:12060385; http://dx.doi.org/10.1046/j.1523-1747.2002.01786.x
2. Zangen R, Ratovitski EA, Sidransky D. DeltaNp63α levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4:1313-5; PMID:16123597; http://dx.doi.org/10.4161/cc.4.10.2066
3. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
4. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70:1793-803; PMID:20145152; http://dx.doi. org/10.1158/0008-5472.CAN-09- 3112
5. Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family crosstalk meets therapeutic opportunity. Oncotarget 2011; 2:259-64; PMID:21436470
6. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005; 5:15-27; PMID:15720258; http://dx.doi. org/10.2174/1568011053352587
7. Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007; 26:4749-60; PMID:17297441; http://dx.doi.org/10.1038/sj. onc.1210289
8. Sheng Z, Evans SK, Green MR. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy? Oncotarget 2010; 1:457-60; PMID:21311102
9. Zeng SX, Dai MS, Keller DM, Lu H. SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J 2002; 21:5487-97; PMID:12374749; http://dx.doi.org/10.1093/emboj/cdf540
10. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. P63 and p73 are required for TP53-dependent apoptosis in response to DNA damage. Nature 2002; 416:560-4; PMID:11932750; http://dx.doi.org/10.1038/416560a
11. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9:45-56; PMID:16413471; http://dx.doi.org/10.1016/j.ccr.2005. 12.013
12. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006; 24:841-51; PMID:17189187; http://dx.doi.org/10.1016/j.molcel.2006.11. 026
13. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 2006; 24:827-39; PMID:17189186; http://dx.doi.org/10.1016/j. molcel.2006.11.021
14. Miyamoto N, Izumi H, Noguchi T, Nakajima Y, Ohmiya Y, Shiota M, et al. Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 2008; 283:18218-26; PMID:18458078; http://dx.doi.org/10.1074/jbc. M802332200
15. Maclaine NJ, Hupp TR. The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY) 2009; 1:490-502; PMID:20157532
16. Martin AG, Trama J, Crighton D, Ryan KM, Fearnhead HO. Activation of p73 and induction of Noxa by DNA damage requires NF-κB. Aging (Albany NY) 2009; 1:335-49; PMID:20195489
17. Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K, et al. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007; 26:5194-203; PMID:17297437; http://dx.doi. org/10.1038/sj.onc.1210326
18. Vousden KH. Partners in death: a role for p73 and NFκB in promoting apoptosis. Aging (Albany, NY Online) 2009; 1:275-7
19. Muppani N, Nyman U, Joseph B. TAp73α protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death. Oncotarget 2011; 2:1145-54; PMID:22201672
20. Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, et al. ATM kinase is a master switch for the Δ Np63 α phosphorylation/ degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 2008; 7:2846-55; PMID:18769144; http://dx.doi.org/10.4161/cc. 7.18.6627
21. Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO, et al. ΔNp63α confers tumor cell resistance to cisplatin treatment through the transcriptional regulation of AKT. Cancer Res 2011; 71:1167-76; PMID:21266360; http://dx.doi.org/10.1158/0008-5472.CAN-10-1481
22. Nordentoft I, Dyrskjøt L, Bødker JS, Wild PJ, Hartmann A, Bertz S, et al. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer. BMC Cancer 2011; 11:135; PMID:21489314; http://dx.doi. org/10.1186/1471-2407-11-135
23. Garand C, Guay D, Sereduk C, Chow D, Tsofack SP, Langlois M, et al. An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells. Cancer Sci 2011; 102:1410-7; PMID:21466612; http://dx.doi.org/10.1111/j.1349-7006.2011. 01948.x
24. Shiota M, Yokomizo A, Tada Y, Uchiumi T, Inokuchi J, Tatsugami K, et al. P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci 2010; 101:1797-806; PMID:20491776; http://dx.doi.org/10.1111/j.1349-7006.2010. 01598.x
25. Huang Y, Chuang AY, Romano RA, Liegeois NJ, Sinha S, Trink B, et al. Phospho-ΔNp63α/NF-Y protein complex transcriptionally regulates DDIT3 expression in squamous cell carcinoma cells upon cisplatin exposure. Cell Cycle 2010; 9:332-42; http://dx.doi. org/10.4161/cc.9.2.10432
26. Huang YP, Chuang A, Hao H, Talbot CC, Trink B, Sidransky D, et al. Phospho-ΔNp63α is a key regulator of cisplatin-induced microRNAome in head and neck squamous cell carcinoma cells. Cell Death Differ 2011; 18:1220-30; PMID:21274007; http://dx.doi. org/10.1038/cdd.2010.188
27. Huang Y, Guerrero-Preston R, Ratovitski EA. Phospho-ΔNp63α- dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle 2012; 11:1247-59; PMID:22356768; http://dx.doi.org/10. 4161/cc.11.6.19670
28. Huang Y, Chuang AY, Ratovitski EA. Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure. Cell Cycle 2011; 10:3938-47; PMID:22071691; http://dx.doi. org/10.4161/cc.10.22.18107
29. Huang Y, Jeong JS, Okamura J, Sook-Kim M, Zhu H, Guerrero-Preston R, et al. Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance. Cell Cycle 2012; 11:2367-79; PMID:22672905; http://dx.doi.org/10.4161/cc.20863
30. Huang Y, Ratovitski EA. Phospho-ΔNp63α/Rpn13-dependent regulation of LKB1 degradation modulates autophagy in cancer cells. Aging (Albany, NY Online) 2010; 2:959-68
31. Ku WC, Chiu SK, Chen YJ, Huang HH, Wu WG, Chen YJ. Complementary quantitative proteomics reveals that transcription factor AP-4 mediates E-box-dependent complex formation for transcriptional repression of HDM2. Mol Cell Proteomics 2009; 8:2034-50; PMID:19505873; http://dx.doi. org/10.1074/mcp.M900013-MCP200
32. Yoshida K, Ozaki T, Furuya K, Nakanishi M, Kikuchi H, Yamamoto H, et al. ATM-dependent nuclear accumulation of IKK-α plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 2008; 27:1183-8; PMID:17700524; http://dx.doi.org/10.1038/sj.onc.1210722
33. Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2:535-7; PMID:20876940
34. Seviour EG, Lin SY. The DNA damage response: Balancing the scale between cancer and ageing. Aging (Albany NY) 2010; 2:900-7; PMID:21191148
35. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell 2012; 46:30-42; PMID:22387025; http://dx.doi.org/10.1016/j.molcel. 2012.01.020
36. Leung AK, Sharp PA. Micro RNA functions in stress responses. Mol Cell 2010; 40:205-15; PMID:20965416; http://dx.doi.org/10.1016/j.molcel. 2010.09.027
37. Le MT, Shyh-Chang N, Khaw SL, Chin L, Teh C, Tay J, et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNAtarget gene pairs. PLoS Genet 2011; 7:e1002242; PMID:21935352; http://dx.doi.org/10.1371/journal. pgen.1002242
38. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011; 20:187-99; PMID:21840484; http://dx.doi.org/10.1016/j. ccr.2011.06.016
39. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012; 56:622-31; PMID:22370893; http://dx.doi.org/10.1002/hep.25679
40. Marasa BS, Srikantan S, Martindale JL, Kim MM, Lee EK, Gorospe M, et al. MicroRNA profiling in human diploid fibroblasts uncovers miR-519 role in replicative senescence. Aging (Albany NY) 2010; 2:333-43; PMID:20606251
41. Ashraf SI, Ip YT. Transcriptional control: repression by local chromatin modification. Curr Biol 1998; 8:R683-6; PMID:9768353; http://dx.doi.org/10.1016/ S0960-9822(98)70435-X
42. Nguyen TT, Cho K, Stratton SA, Barton MC. Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the α-fetoprotein gene. Mol Cell Biol 2005; 25:2147-57; PMID:15743813; http://dx.doi. org/10.1128/MCB.25.6.2147-2157.2005
43. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25:1125-42; PMID:16314846; http://dx.doi. org/10.1038/sj.onc.1209080
44. Shalgi R, Brosh R, Oren M, Pilpel Y, Rotter V. Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate. Aging (Albany NY) 2009; 1:762-70; PMID:20157565
45. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, et al. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 2009; 7:210-20; PMID:19208743; http://dx.doi. org/10.1158/1541-7786.MCR-08-0255
46. Suenaga Y, Ozaki T, Tanaka Y, Bu Y, Kamijo T, Tokuhisa T, et al. TATA-binding Protein (TBP)-like Protein Is Engaged in Etoposide-induced Apoptosis through Transcriptional Activation of Human TAp63 Gene. J Biol Chem 2009; 284:35433-40; PMID:19858204; http://dx.doi.org/10.1074/jbc.M109.050047
47. Wang B, Xiao Z, Ko HL, Ren EC. The p53 response element and transcriptional repression. Cell Cycle 2010; 9:870-9; PMID:20160511; http://dx.doi. org/10.4161/cc.9.5.10825
48. Mallette FA, Calabrese V, Ilangumaran S, Ferbeyre G. SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY) 2010; 2:445-52; PMID:20622265
49. CIP1 promoter blocks transcription resulting in cell death. Oncotarget 2011; 2:1094-108; PMID:22190353
50. Bedford DC, Brindle PK. Is histone acetylation the most important physiological function for CBP and p300? Aging (Albany NY) 2012; 4:247-55; PMID:22511639
51. Imbriano C, Gnesutta N, Mantovani R. The NF-Y/p53 liaison: Well beyond repression. Biochim Biophys Acta 2012; 1825:131-9; PMID:22138487
52. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 2012; 19:1992-2002; PMID:22790872; http://dx.doi. org/10.1038/cdd.2012.89
53. Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010; 10:788-95; PMID:20686362; http://dx.doi.org/10.4161/cbt.10.8.12913
54. Hirano G, Izumi H, Kidani A, Yasuniwa Y, Han B, Kusaba H, et al. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells. Mol Cancer Res 2010; 8:864-72; PMID:20530585; http://dx.doi.org/10.1158/1541- 7786.MCR-09-0458
55. Gomes AR, Brosens JJ, Lam EW. Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008; 7:3133-6; PMID:18927504; http://dx.doi.org/10.4161/cc.7.20.6920
56. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010; 8:24-34; PMID:20068070; http://dx.doi.org/10.1158/1541-7786.MCR-09- 0432
57. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011; 71:4412-22; PMID:21571862; http://dx.doi.org/10.1158/0008- 5472.CAN-10-4111
58. Davies AH, Dunn SE. YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention. Oncotarget 2011; 2:401-6; PMID:21576761
59. Sen T, Chang X, Sidransky D, Chatterjee A. Regulation of ΔNp63α by NFκB. Cell Cycle 2010; 9:4841-7; PMID:21088498; http://dx.doi.org/10.4161/cc.9.24.14093
60. Covic M, Hassa PO, Saccani S, Buerki C, Meier NI, Lombardi C, et al. Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappa Bdependent gene expression. EMBO J 2005; 24:85-96; PMID:15616592; http://dx.doi.org/10.1038/sj.emboj.7600500
61. Wu J, Cui N, Wang R, Li J, Wong J. A role for CARM1-mediated histone H3 arginine methylation in protecting histone acetylation by releasing corepressors from chromatin. PLoS One 2012; 7:e34692; PMID:22723830; http://dx.doi.org/10. 1371/journal. pone.0034692
62. Lee YH, Stallcup MR. Roles of protein arginine methylation in DNA damage signaling pathways is CARM1 a life-or-death decision point? Cell Cycle 2011; 10:1343-4; PMID:21445011; http://dx.doi. org/10.4161/cc.10.9.15379
63. Chatterjee A, Sen T, Chang X, Sidransky D. Yes-associated protein 1 regulates the stability of DeltaNp63α. Cell Cycle 2010; 9:162-7; PMID:20016275; http://dx.doi.org/10.4161/cc.9.1.10321
64. Lee KK, Yonehara S. Identification of mechanism that couples multisite phosphorylation of Yes-associated protein (YAP) with transcriptional coactivation and regulation of apoptosis. J Biol Chem 2012; 287:9568-78; PMID:22308035; http://dx.doi.org/10.1074/jbc. M111.296954
65. Wu ZZ, Sun NK, Chao CC. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis. J Cell Physiol 2011; 226:2415-28; PMID:21660965; http://dx.doi. org/10.1002/jcp.22589
66. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011; 2:669-83; PMID:21941025
67. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012; 72:3091-104; PMID:22505648; http://dx.doi. org/10.1158/0008-5472.CAN-11-3546
68. Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ, et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ 2011; 18:1771-9; PMID:21546904; http://dx.doi. org/10.1038/cdd.2011.48
69. Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 2012; 31:583-94; PMID:21685935
70. Wang M, Gartel AL. The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA. Oncotarget 2011; 2:1218-26; PMID:22203467
71. Garriga-Canut M, Roopra A, Buckley NJ. The basic helix-loop-helix protein, sharp-1, represses transcription by a histone deacetylase-dependent and histone deacetylase-independent mechanism. J Biol Chem 2001; 276:14821-8; PMID:11278948; http://dx.doi. org/10.1074/jbc.M011619200
72. Liu JJ, Chung TK, Li J, Taneja R. Sharp-1 modulates the cellular response to DNA damage. FEBS Lett 2010; 584:619-24; PMID:20006609; http://dx.doi. org/10.1016/j.febslet.2009.12.011
73. Falvella FS, Colombo F, Spinola M, Campiglio M, Pastorino U, Dragani TA. BHLHB3: a candidate tumor suppressor in lung cancer. Oncogene 2008; 27:3761-4; PMID:18223678; http://dx.doi. org/10.1038/sj.onc.1211038
74. Wu Y, Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, et al. BHLH transcription factor DEC2 regulates pro-apoptotic factor Bim in human oral cancer HSC-3 cells. Biomed Res 2012; 33:75-82; PMID:22572381; http://dx.doi.org/10.2220/biomedres. 33.75
75. Oswald F, Winkler M, Cao Y, Astrahantseff K, Bourteele S, Knöchel W, et al. RBP-Jkappa/SHARP recruits CtIP/CtBP corepressors to silence Notch target genes. Mol Cell Biol 2005; 25:10379-90; PMID:16287852; http://dx.doi.org/10. 1128/MCB.25.23.10379-10390.2005
76. Madison DL, Lundblad JR. C-terminal binding protein and poly(ADP)ribose polymerase 1 contribute to repression of the p21(waf1/cip1) promoter. Oncogene 2010; 29:6027-39; PMID:20711239; http://dx.doi. org/10.1038/onc.2010.338
77. Jeon BN, Choi WI, Yu MY, Yoon AR, Kim MH, Yun CO, et al. ZBTB2, a novel master regulator of the p53 pathway. J Biol Chem 2009; 284:17935-46; PMID:19380588; http://dx.doi.org/10.1074/jbc. M809559200
78. 2/M promoters, via p53 C-terminal lysines. J Biol Chem 2006; 281:2347-57; PMID:16293626; http://dx.doi.org/10.1074/jbc. M507712200
79. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007; 67:3145-52; PMID:17409421; http://dx.doi.org/10.1158/0008-5472.CAN-06-4397
80. Bansal N, Kadamb R, Mittal S, Vig L, Sharma R, Dwarakanath BS, et al. Tumor suppressor protein p53 recruits human Sin3B/HDAC1 complex for down-regulation of its target promoters in response to genotoxic stress. PLoS One 2011; 6:e26156; PMID:22028823; http://dx.doi.org/10.1371/journal.pone. 0026156
81. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, Kenner L, et al. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 2011; 10:406-12; PMID:21270520; http://dx.doi. org/10.4161/cc.10.3.14712
82. Ramsey MR, He L, Forster N, Ory B, Ellisen LW. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res 2011; 71:4373-9; PMID:21527555; http://dx.doi.org/10.1158/0008-5472.CAN-11-0046